We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

October 7, 2022

Five Expert Insights from the HealthXL Community

Commentary
HealthXL Team & HealthXL Community
&

Over the past month, our HealthXL community members discussed new distribution channels for DTx, seeking capital for DTx products and digital health pharma partnerships, among other topics. We’ve put together a snapshot of five expert insights from these meetings.

#1 On alternative distribution channels for DTx: The activation and engagement of patients with DTx is challenging, therefore pharmacies and telehealth platforms could serve as an adoption ‘booster’ to increase product recommendations, as well as product compliance and long-term engagement. Pharmacies could be a great avenue for over the counter (OTC) DTx solutions where there is no prescription required, particularly with drugs that have a companion DTx. However, a pharmacist needs to have the willingness to engage with the therapy, which is challenging at the moment due to the lack of incentives. On the other hand, telehealth platforms seem like a natural fit for DTx solutions as a distribution channel. However, with both of these alternative distribution models the suitability of each depends on the use case - the type of DTx, the country's policy around the role of pharmacies, and how the telehealth platform will be deployed.

#2 On obtaining capital for DTx: Investors need to see clear evidence generation and regulatory strategies. It is important to show that there is a scientific base and market need for the product, but even though showing the data is key, being confident about it is essential.  Different types of investors will have different approaches and want to see different things. Companies should therefore adapt their pitch to each investor in order to show them evidence and (likely) commercial outcomes they expect to see.  

#3 On generating impactful evidence for DTx:  DTx companies should identify the clinical endpoints that will support their commercial model at the beginning. In order to achieve that, it is key to understand what the value is for the different stakeholders/buyers they want to target. For example, if payers are important for the company’s commercial model, they will need to generate evidence that shows the economic value in the relevant patient population. DTx companies can learn from Pharma and MedTech when it comes to economic modeling and early validation of the product potential. It’s important to start using health economics modeling early on, validate the assumptions about the product with medical affairs, and validate the market access and pricing assumptions. This way the digital health company will better align their commercial strategy with their clinical operations efforts from the get go.

#4 On seeking partnerships with pharma: Developing a bidirectional relationship with the pharma partner is key to ensure the digital health company also benefits from the collaboration. Digital Health companies need to be careful to avoid becoming an agency/vendor vs. a DTx company, as the line is very thin when working with pharma. To establish a true partnership, both parties need to be clear on what they want to achieve in the short and long term; sometimes partnerships fail because there was no alignment on the long-term goals, but rather, just a focus on short/mid-term achievements. Digital health companies should make sure to find a long-term partner with a shared long-term vision.

#5 On building a relationship with the FDA: DTx companies should try and have open conversations with the FDA early on. In these conversations, DTx companies should define the purpose of their product and be very specific. For example, if the DTx company has chosen a clinical endpoint that has not previously been validated, they need to provide a justification on why that endpoint is relevant and provide sufficient information to make sure the FDA agrees that these endpoints are appropriate for the clinical study of the product. It may be the case that the FDA doesn't agree with the primary endpoints selected by the company to show the product’s safety and effectiveness. In that case, the best option is to communicate directly with the FDA to understand their thought process and what they are looking for, as it may be possible that they accept the secondary endpoints instead. Therefore, having open conversations and building a relationship with the FDA can be very beneficial in the development of the product.

Want to join the conversation? Check out our platform for upcoming meetings and events.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Key Considerations for Inclusion on the Evernorth Digital Health Formulary

13th December @ 10:45AM EDT

How do DTx products get listed on a formulary? And what happens next? Join this masterclass to hear from Mark Bini, the visionary who helped devise Evernorth's Digital Health Formulary.

Featuring
Mark Bini
Mark Bini
Chief Patient Experience Officer at Evernorth
Featuring
Mark Bini
Mark Bini
Chief Patient Experience Officer at Evernorth
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: Future EU Regulations for AI in Medical Devices

13th December @ 10AM GMT / 6PM AWST

Are you trying to commercialize AI-based digital health solutions in the European Union (EU)? Would you like to learn practical steps on how to navigate the EU regulations for AI in medical devices? Join us in this masterclass led by Erik Vollebregt (Partner at Axon Lawyers) to deep dive into this topic.

Featuring
Erik Vollebregt
Erik Vollebregt
Partner, Axon Lawyers
Featuring
Erik Vollebregt
Erik Vollebregt
Partner, Axon Lawyers
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Innovative Distribution Strategies for DTx

14th December @ 10:45 AM EDT

Currently, there is no one-size-fits-all strategy for DTx distribution. Join HealthXL in this meeting to discuss this topic further with your peers working in this space.

Featuring
Francesca Wuttke
Francesca Wuttke
CEO and Founder, nen Health
Featuring
Francesca Wuttke
Francesca Wuttke
CEO and Founder, nen Health
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)
Digital Therapeutics (DTx)

Masterclass: DTx Access Negotiation and Contracting with Commercial Health Plans in the US

15th December @ 10:45 AM EDT

Are you seeking reimbursement of a DTx solution in the US? Join this Masterclass led by Mike Pace to deep dive into this topic with your peers working in this space.

Featuring
Michael Pace
Michael Pace
CEO & Founder at PalmHealth.co
Featuring
Michael Pace
Michael Pace
CEO & Founder at PalmHealth.co

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Telemedicine & Virtual Care Delivery
12th December @ 10:45AM EDT

Masterclass: Partnering with Health Systems in Digital Health

Are you working in digital health and looking for successful partnerships with health systems? Join this meeting to deep dive into this topic with other senior leaders in this field.

Michael Freni
Featuring
Michael Freni
Vice President, Business Development, Innovation & Venture Partner, A.I. Digital Innovation Fund, Mass General Brigham
Digital Therapeutics (DTx)
13th December @ 10:45AM EDT

Masterclass: Key Considerations for Inclusion on the Evernorth Digital Health Formulary

How do DTx products get listed on a formulary? And what happens next? Join this masterclass to hear from Mark Bini, the visionary who helped devise Evernorth's Digital Health Formulary.

Mark Bini
Featuring
Mark Bini
Chief Patient Experience Officer at Evernorth
Digital Therapeutics (DTx)
13th December @ 10AM GMT / 6PM AWST

Masterclass: Future EU Regulations for AI in Medical Devices

Are you trying to commercialize AI-based digital health solutions in the European Union (EU)? Would you like to learn practical steps on how to navigate the EU regulations for AI in medical devices? Join us in this masterclass led by Erik Vollebregt (Partner at Axon Lawyers) to deep dive into this topic.

Erik Vollebregt
Featuring
Erik Vollebregt
Partner, Axon Lawyers
Digital Therapeutics (DTx)
14th December @ 10:45 AM EDT

Innovative Distribution Strategies for DTx

Currently, there is no one-size-fits-all strategy for DTx distribution. Join HealthXL in this meeting to discuss this topic further with your peers working in this space.

Francesca Wuttke
Featuring
Francesca Wuttke
CEO and Founder, nen Health

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.